562 related articles for article (PubMed ID: 18266225)
1. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
4. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
5. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
6. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
7. Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina.
Villegas Rubio JA; Cacciavillano W; Rose A; Zubizarreta P; Scopinaro M
J Pediatr Hematol Oncol; 2017 Oct; 39(7):e349-e352. PubMed ID: 28937522
[TBL] [Abstract][Full Text] [Related]
8. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
10. High-dose leucovorin as sole therapy for methotrexate toxicity.
Flombaum CD; Meyers PA
J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
[TBL] [Abstract][Full Text] [Related]
11. [High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].
Sampi K; Hattori M
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1068-73. PubMed ID: 6985194
[TBL] [Abstract][Full Text] [Related]
12. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
[TBL] [Abstract][Full Text] [Related]
13. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
[TBL] [Abstract][Full Text] [Related]
14. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
Kickinger W; Ritschl P; Kotz R
Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
[TBL] [Abstract][Full Text] [Related]
15. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
16. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
18. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
19. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
